Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
US Market
Holding AVTE?
Track your performance easily

Aerovate Therapeutics (AVTE) Income Statement

124 Followers

Aerovate Therapeutics Income Statement

Last quarter (Q2 2024), Aerovate Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Aerovate Therapeutics's net income was $-24.77M. See Aerovate Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 94.22M$ 81.41M$ 53.24M$ 23.02M$ 8.89M$ 3.33M
Operating Income
$ -94.22M$ -81.41M$ -53.24M$ -23.02M$ -8.89M$ -3.33M
Net Non Operating Interest Income Expense
$ 6.34M$ 5.95M$ 1.83M$ 65.00K$ -75.00K$ 0.00
Other Income Expense
$ 569.00K$ -1.00K$ -79.00K$ 3.00K$ -647.00K$ 1.00K
Pretax Income
$ -88.15M$ -75.47M$ -51.49M$ -22.96M$ -9.61M$ -3.33M
Tax Provision
$ 56.00K$ 56.00K$ 25.00K$ 3.00K$ 0.00-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -87.94M$ -75.52M$ -51.51M$ -23.02M$ -9.76M$ -3.33M
Basic EPS
$ -3.13$ -2.87$ -2.10$ -1.87$ -4.11$ -1.40
Diluted EPS
$ -3.13$ -2.87$ -2.10$ -1.87$ -4.11$ -1.40
Basic Average Shares
$ 111.93M$ 26.33M$ 24.47M$ 12.29M$ 2.37M$ 2.37M
Diluted Average Shares
$ 111.93M$ 26.33M$ 24.47M-$ 2.37M$ 2.37M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 94.22M$ 81.41M$ 53.24M$ 23.02M$ 8.89M$ 3.33M
Net Income From Continuing And Discontinued Operation
$ -87.94M$ -75.52M$ -51.51M$ -22.96M$ -9.61M$ -3.33M
Normalized Income
$ -53.71M$ -59.62M-$ -18.14M$ -9.61M$ -3.33M
Interest Expense
----$ 75.00K$ 0.00
EBIT
$ -94.22M$ -81.41M$ -53.24M$ -22.90M$ -8.89M$ -3.33M
EBITDA
$ -94.11M$ -81.31M$ -53.17M$ -22.87M$ -8.89M$ -3.33M
Currency in USD

Aerovate Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis